BeOne Medicines Ltd. (ONC) Earnings History
Profitable13 years of earnings data (2013–2025) · Positive TTM net income
Loading earnings history...
BeOne Medicines Ltd. (ONC) Earnings Overview
As of June 28, 2026, BeOne Medicines Ltd. (ONC) reported trailing twelve-month net income of $513M, reflecting +637.4% year-over-year growth. The company earned $4.43 per diluted share over the past four quarters, with a net profit margin of 5.4%.
Looking at the long-term picture, ONC's historical earnings data spans multiple years. The company achieved its highest annual net income of $287M in fiscal 2025, representing a new all-time high.
BeOne Medicines Ltd. maintains positive profitability with a gross margin of 87.5%, operating margin of 8.4%, and net margin of 5.4%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including ZYME (-$103M net income, -76.6% margin), RCUS (-$369M net income, -142.9% margin), TGTX ($462M net income, 72.6% margin), ONC has outperformed on profitability metrics. Compare ONC vs ZYME →
ONC Earnings vs Peers
Earnings metrics vs comparable public companies
ONC Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $287M | +144.5% | $447M | $32.89 | 5.4% | 8.4% |
| 2024 | -$645M | +26.9% | -$568M | $-6.12 | -16.9% | -14.9% |
| 2023 | -$882M | +56.0% | -$1.21B | $-8.45 | -35.9% | -49.1% |
| 2022 | -$2.00B | -37.5% | -$1.79B | $-19.37 | -141.5% | -126.4% |
| 2021 | -$1.46B | +10.3% | -$1.44B | $-15.21 | -123.9% | -122.3% |
| 2020 | -$1.62B | -71.3% | -$1.66B | $-19.11 | -526.1% | -536.7% |
| 2019 | -$949M | -40.8% | -$960M | $-15.86 | -221.5% | -224.2% |
| 2018 | -$674M | -623.7% | -$706M | $-12.09 | -339.9% | -356.1% |
| 2017 | -$93M | +21.9% | -$98M | $-2.21 | -39.1% | -41.3% |
| 2016 | -$119M | -108.8% | -$117M | $-3.90 | -11141.8% | -10940.2% |
| 2015 | -$57M | -212.4% | -$57M | $-1.82 | -647.7% | -643.7% |
| 2014 | -$18M | -143.9% | -$16M | $-0.35 | -140.2% | -120.9% |
| 2013 | -$7M | - | -$5M | $-1.43 | -67.2% | -49.0% |
Download Data
Export ONC earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ONC — Frequently Asked Questions
Quick answers to the most common questions about buying ONC stock.
What is ONC earnings per share (EPS)?
ONC trailing twelve-month (TTM) diluted EPS is $4.43, reflecting +637.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2025 is available in the table on this page.
What is BeOne Medicines Ltd.'s net income?
BeOne Medicines Ltd. (ONC) trailing twelve-month net income is $513M as of 2025. Earnings grew +637.4% year-over-year.
Is ONC profitable?
Yes, ONC is profitable with a TTM net income of $513M and a net profit margin of +5.4%.
What is ONC's earnings growth rate?
ONC compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2025.
What are ONC's profit margins?
BeOne Medicines Ltd. net profit margin is +5.4%, operating margin is +8.4%, and gross margin is +87.5%. Margins are within a typical range for the sector. Return on Equity is +7.5%.
Is ONC growing earnings?
Yes, ONC earnings are accelerating — EPS growth of +637.4% exceeds the 5-year CAGR of N/A. TTM net income reached $513M. Earnings momentum is strengthening.
What was ONC's best earnings year?
BeOne Medicines Ltd.'s highest annual net income on record is $287M, achieved in fiscal year 2025. Earnings history on this page spans 2013 to 2025 and includes all annual and quarterly figures.
What were ONC's earnings last quarter?
ONC's most recent reported quarter was Q1 2026. Net income was $227M with diluted EPS of $25.48. For a full breakdown of all quarters, see the quarterly earnings table on this page.